2025.10.24 (±Ý)
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦46È£
µ¥Àϸ®¸®Ä¡¾Øµå·°Å° 2024-08-06
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦45È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦44È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦43È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦42È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦41È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦40È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦39È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦38È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦37È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦36È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦35È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦34È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦33È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦32È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦31È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦30È£
µ¥Àϸ®¸®Ä¡¾Øµå·°Å° 2024-08-04
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦29È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦28È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦27È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦226È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦96È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦223È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦225È£
¸®¾ÞÄÝ)Çǽº·¹ÅÍ Á¦50È£
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule
½Ã¸³¼ö¼Ã»¼Ò³â¼¾ÅÍ, 2025 Á¦4ȸ û¼Ò³â¸ÞÀÌÄ¿°æÁø´ëȸ ¡®YOUTH MAKER¡¯ ¼ºÈ²¸®¿¡ °³ÃÖ
TRM ·¦½º, ½Ì°¡Æ÷¸£ »çÀ̹öº¸¾Èû°ú Çù·ÂÇØ ºí·ÏüÀÎ ºÐ¾ß ±¹°¡ »çÀ̹ö À§Çù ÀÎÅÚ¸®Àü½º °È ÃßÁø
°æºÏ´ë Àι®»çȸÀ¶ÇÕÀÎÀç¾ç¼º»ç¾÷´Ü, ´ë±¸ÀüÅë½ÃÀåÁøÈïÀç´Ü°ú Çù·ÂÇØ ·ÎÄà ũ¸®¿¡ÀÌÅÍ ÀÎÀç ¾ç¼º
Aptiv Unveils Gen 8 Radars to Power the Future of ADAS